Shilpa Medicare Future Growth

Future criteria checks 5/6

Shilpa Medicare is forecast to grow earnings and revenue by 71.2% and 29% per annum respectively. EPS is expected to grow by 70.6% per annum. Return on equity is forecast to be 11.4% in 3 years.

Key information

71.2%

Earnings growth rate

70.6%

EPS growth rate

Pharmaceuticals earnings growth	18.2%
Revenue growth rate	29.0%
Future return on equity	11.4%
Analyst coverage	Low
Last updated	16 Sep 2024

Recent future growth updates

Recent updates

What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You

Sep 12

Shilpa Medicare Limited's (NSE:SHILPAMED) 29% Price Boost Is Out Of Tune With Revenues

Jul 05

What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You

Apr 12

Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up

Feb 21

Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt

Jan 02

These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively

Jul 17

Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt

Mar 17

Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)

Sep 22

Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why

Sep 21

Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Jun 17

If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late

May 31

Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Mar 07

Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year

Feb 20

Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Jan 26

Here's Why I Think Shilpa Medicare (NSE:SHILPAMED) Is An Interesting Stock

Jan 14

Shilpa Medicare (NSE:SHILPAMED) Shareholders Have Enjoyed A 54% Share Price Gain

Jan 03

Earnings and Revenue Growth Forecasts

NSEI:SHILPAMED - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2027	27,793	6,339	N/A	N/A	1
3/31/2026	17,739	3,833	N/A	N/A	2
3/31/2025	14,037	1,568	N/A	N/A	2
6/30/2024	11,839	448	N/A	N/A	N/A
3/31/2024	11,531	319	-492	1,353	N/A
12/31/2023	11,248	-7	N/A	N/A	N/A
9/30/2023	11,008	-119	-30	2,523	N/A
6/30/2023	10,491	-321	N/A	N/A	N/A
3/31/2023	10,517	-325	-467	1,799	N/A
12/31/2022	11,286	51	N/A	N/A	N/A
9/30/2022	11,384	213	-1,620	1,651	N/A
6/30/2022	11,693	599	N/A	N/A	N/A
3/31/2022	11,469	607	-2,267	1,051	N/A
12/31/2021	10,135	395	N/A	N/A	N/A
9/30/2021	9,324	376	-2,589	478	N/A
6/30/2021	9,156	631	N/A	N/A	N/A
3/31/2021	9,016	1,478	-3,073	469	N/A
12/31/2020	9,135	1,739	N/A	N/A	N/A
9/30/2020	9,591	2,213	-2,704	793	N/A
6/30/2020	9,698	2,267	N/A	N/A	N/A
3/31/2020	9,082	1,562	-2,249	1,244	N/A
12/31/2019	8,876	1,455	N/A	N/A	N/A
9/30/2019	8,241	1,029	-3,065	819	N/A
6/30/2019	6,962	944	N/A	N/A	N/A
3/31/2019	7,337	1,123	-1,532	1,468	N/A
12/31/2018	7,693	1,193	N/A	N/A	N/A
9/30/2018	7,814	1,281	N/A	N/A	N/A
6/30/2018	8,211	1,167	N/A	N/A	N/A
3/31/2018	7,894	1,052	N/A	449	N/A
12/31/2017	7,756	1,133	N/A	N/A	N/A
9/30/2017	7,731	1,149	N/A	N/A	N/A
6/30/2017	7,787	1,190	N/A	N/A	N/A
3/31/2017	7,795	1,076	N/A	375	N/A
12/31/2016	7,565	1,048	N/A	N/A	N/A
9/30/2016	7,735	1,153	N/A	N/A	N/A
6/30/2016	7,369	1,024	N/A	N/A	N/A
3/31/2016	7,166	1,083	N/A	1,287	N/A
12/31/2015	6,867	886	N/A	N/A	N/A
9/30/2015	6,430	776	N/A	N/A	N/A
6/30/2015	6,234	728	N/A	N/A	N/A
3/31/2015	6,138	737	N/A	688	N/A
12/31/2014	6,145	731	N/A	N/A	N/A
9/30/2014	6,143	798	N/A	N/A	N/A
6/30/2014	5,966	787	N/A	N/A	N/A
3/31/2014	5,714	757	N/A	700	N/A
12/31/2013	5,025	664	N/A	N/A	N/A
9/30/2013	4,422	556	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SHILPAMED's forecast earnings growth (71.2% per year) is above the savings rate (6.7%).

Earnings vs Market: SHILPAMED's earnings (71.2% per year) are forecast to grow faster than the Indian market (17.2% per year).

High Growth Earnings: SHILPAMED's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SHILPAMED's revenue (29% per year) is forecast to grow faster than the Indian market (10.1% per year).

High Growth Revenue: SHILPAMED's revenue (29% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SHILPAMED's Return on Equity is forecast to be low in 3 years time (11.4%).

Shilpa Medicare Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Price target decreased to ₹355

Price target increased to ₹511

Price target lowered to ₹543

Recent updates

What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You

Shilpa Medicare Limited Completes Phase 1 Trial for Recombinant Human Albumin (rHA) 20%

Shilpa Medicare Limited Announces the Approval of Its Second Nda, Injection, by Usfda

Shilpa Medicare Limited, Annual General Meeting, Sep 17, 2024

First quarter 2025 earnings released: EPS: ₹1.46 (vs ₹0.14 in 1Q 2024)

Shilpa Medicare Limited, Annual General Meeting, Sep 17, 2024

Shilpa Medicare Limited to Report Q1, 2025 Results on Aug 08, 2024

Shilpa Medicare Limited's (NSE:SHILPAMED) 29% Price Boost Is Out Of Tune With Revenues

Full year 2024 earnings released: EPS: ₹3.67 (vs ₹3.74 loss in FY 2023)

Shilpa Medicare Limited to Report Q4, 2024 Results on May 23, 2024

What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You

Shilpa Medicare Limited has filed a Follow-on Equity Offering in the amount of INR 5 billion.

Shilpa Medicare Limited has filed a Follow-on Equity Offering in the amount of INR 5 billion.

Shilpa Medicare Limited has filed a Follow-on Equity Offering in the amount of INR 5 billion.

Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up

Third quarter 2024 earnings released: EPS: ₹0.53 (vs ₹0.76 loss in 3Q 2023)

Shilpa Medicare Limited to Report Q3, 2024 Results on Feb 08, 2024

Shilpa Medicare Limited and Celltrion, Inc. Announce Arbitration

Shilpa Medicare Limited and Celltrion, Inc. Announce Arbitration

Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt

Second quarter 2024 earnings released: EPS: ₹0.19 (vs ₹2.15 loss in 2Q 2023)

Shilpa Medicare Limited to Report Q2, 2024 Results on Nov 10, 2023

Shilpa Medicare Limited Launches Naturally Derived Option for the Treatment of Oral Mucositis in India Under the Brand Name Oraal

Shilpa Medicare Limited, Annual General Meeting, Sep 29, 2023

First quarter 2024 earnings released: EPS: ₹0.14 (vs ₹0.10 in 1Q 2023)

Shilpa Medicare Limited to Report Q1, 2024 Results on Aug 10, 2023

These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively

New minor risk - Share price stability

Full year 2023 earnings released: ₹3.74 loss per share (vs ₹7.26 profit in FY 2022)

Shilpa Medicare Limited Announces New Drug Application for Pemetrexed Injection 1000 mg/100 ml, 500 mg/50 mg/50 mg & 100 mg/10 mg/10 mgl, Ready to Use Form Form Formulation Is Approved By US FDA

Shilpa Medicare Limited Announces US FDA GMP Inspection Cleared with VAI Classification

Shilpa Medicare Limited to Report Q4, 2023 Results on May 25, 2023

Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt

Shilpa Medicare Limited, Unit Vi, Bengaluru Facility Has Successfully Registered with Ministry of Health, United Arab Emirates

Third quarter 2023 earnings released

Shilpa Medicare Limited to Report Q3, 2023 Results on Feb 14, 2023

Shilpa Medicare Limited announces Launch of its New Brand Capebel (Capecitabine 1000 Mg Dispersible Tablet)

Shilpa Medicare Limited's Unit IV Facility Receives Health Canada GMP Approval

Second quarter 2023 earnings released: ₹2.15 loss per share (vs ₹2.45 profit in 2Q 2022)

Shilpa Medicare Reportedly Plans API Biz Stake Sale

Shilpa Medicare Limited to Report Q2, 2023 Results on Nov 11, 2022

Shilpa Medicare Approves Dividend for the Financial Year Ended 31 March 2022

Shilpa Medicare Limited Announces Change in Directorate

Shilpa Medicare Limited, Analytical Services Division, Nacharam, Hyderabad, Telangana Receives US FDA Clearance for the Facility

Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)

Shilpa Medicare Limited Announces Its Successful Innovation of First in World Topical Hemostatic Spray of Tranexamic Acid Has Received CDSCO Approval

Shilpa Medicare Limited Receives U.S Food and Drug Administration Tentative Approval for Its Anda, Tenofovir Alafenamide Tablets

Upcoming dividend of ₹1.10 per share

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

High number of new directors

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Shilpa Medicare Limited Announces Board Changes

First quarter 2023 earnings released: EPS: ₹0.10 (vs ₹0.19 in 1Q 2022)

Shilpa Medicare Limited, Annual General Meeting, Sep 28, 2022

Shilpa Medicare Limited Appoints Kamal K Sharma as an Additional Independent Director

Price target decreased to ₹355

Shilpa Medicare Limited Appoints Ritu Tiwary as Company Secretary & Compliance Officer

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Shilpa Medicare Limited to Report Fiscal Year 2022 Final Results on May 23, 2022

Shilpa Medicare Limited Via Shilpa Biologicals Private Limited Receive NoC from RCGM, Dept of Biotechnology to Approach the DCGI to Conduct Clinical Studies for its Biosimilar Aflibercept

Shilpa Medicare Limited Announces Board Resignations

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Shilpa Medicare Limited to Report Q3, 2022 Results on Feb 08, 2022

Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load

High number of new directors

Second quarter 2022 earnings released: EPS ₹2.45 (vs ₹5.57 in 2Q 2021)

High number of new directors

Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why

Upcoming dividend of ₹1.10 per share

First quarter 2022 earnings released: EPS ₹0.19 (vs ₹10.59 in 1Q 2021)

Price target increased to ₹511

Shilpa Medicare Limited Receives In-Principle Approval From Defence Research & Development Organisation (DRDO) For Technology Transfer, Manufacture And Supply Of 2-Deoxy-D-Glucose (2DG)